

# Sujun Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12068701/publications.pdf>

Version: 2024-02-01

14  
papers

1,772  
citations

687363

13  
h-index

1058476

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

3762  
citing authors

#	ARTICLE	IF	CITATIONS
1	LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. <i>Cell</i> , 2018, 174, 549-563.e19.	28.9	473
2	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , 2019, 176, 831-843.e22.	28.9	317
3	Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. <i>Cell</i> , 2018, 174, 564-575.e18.	28.9	264
4	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. <i>Nature Cell Biology</i> , 2021, 23, 87-98.	10.3	209
5	Landscape of Noncoding RNA in Prostate Cancer. <i>Trends in Genetics</i> , 2019, 35, 840-851.	6.7	114
6	Transcriptional landscape of the human cell cycle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3473-3478.	7.1	110
7	Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. <i>Nature Genetics</i> , 2020, 52, 1011-1017.	21.4	78
8	G9A promotes tumor cell growth and invasion by silencing CASP1 in non-small-cell lung cancer cells. <i>Cell Death and Disease</i> , 2017, 8, e2726-e2726.	6.3	64
9	KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells. <i>Oncotarget</i> , 2016, 7, 27959-27974.	1.8	40
10	HNRNPM controls circRNA biogenesis and splicing fidelity to sustain cancer cell fitness. <i>ELife</i> , 2021, 10, .	6.0	27
11	Forkhead domain mutations in FOXA1 drive prostate cancer progression. <i>Cell Research</i> , 2019, 29, 770-772.	12.0	25
12	ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells. <i>Oncotarget</i> , 2018, 9, 12020-12034.	1.8	25
13	Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 552-567.	7.0	25
14	Orphan noncoding RNAs: novel regulators and cancer biomarkers. <i>Annals of Translational Medicine</i> , 2019, 7, S21-S21.	1.7	1